Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ozge Gumusay

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 9, 2021
Understanding relevant immune mechanisms in gastrointestinal oncologyBulent Cetin, Ozge Gumusay
The New England Journal of Medicine|June 25, 2020
Pembrolizumab for Early Triple-Negative Breast CancerBulent Cetin, Ozge Gumusay
The New England Journal of Medicine|August 30, 2023
PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial CancerBulent Cetin, Ozge Gumusay
Asian Journal of Psychiatry|May 29, 2020
Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemicBulent Cetin, Sema Rakici, Ozge Gumusay
Current Treatment Options in Oncology|March 22, 2022
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer PatientsBulent Cetin, Chiara A Wabl, Ozge Gumusay
Immunotherapy|June 9, 2023
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkersBulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)|February 9, 2022
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancerBulent Cetin, Chiara A Wabl, Ozge Gumusay
Critical Reviews in Oncology/Hematology|October 15, 2020
The DNA damaging revolutionBulent Cetin, Chiara A Wabl, Ozge Gumusay
Urologia Internationalis|October 26, 2021
Optimal Treatment for Patients with Oligometastatic Prostate CancerBulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)|January 18, 2023
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 9, 2021
Understanding relevant immune mechanisms in gastrointestinal oncologyBulent Cetin, Ozge Gumusay
The New England Journal of Medicine|June 25, 2020
Pembrolizumab for Early Triple-Negative Breast CancerBulent Cetin, Ozge Gumusay
The New England Journal of Medicine|August 30, 2023
PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial CancerBulent Cetin, Ozge Gumusay
Asian Journal of Psychiatry|May 29, 2020
Can you draw the picture of happiness- Treatment of a young woman with breast cancer during the COVID-19 pandemicBulent Cetin, Sema Rakici, Ozge Gumusay
Current Treatment Options in Oncology|March 22, 2022
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer PatientsBulent Cetin, Chiara A Wabl, Ozge Gumusay
Immunotherapy|June 9, 2023
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkersBulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)|February 9, 2022
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancerBulent Cetin, Chiara A Wabl, Ozge Gumusay
Critical Reviews in Oncology/Hematology|October 15, 2020
The DNA damaging revolutionBulent Cetin, Chiara A Wabl, Ozge Gumusay
Urologia Internationalis|October 26, 2021
Optimal Treatment for Patients with Oligometastatic Prostate CancerBulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)|January 18, 2023
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Pageof 5